Mankind Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 07, 2025
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma Limited has announced its 34th Annual General Meeting scheduled for Thursday, August 7, 2025, at 3:30 PM IST, to be held via video conferencing. The agenda includes adoption of audited standalone and consolidated financial statements for FY 2024-25, re-appointment of Mr. Sheetal Arora (who retires by rotation), appointment of M/s Amit Gupta & Associates as Secretarial Auditors for a 5-year term, and ratification of cost auditor M/s M.K. Kulshrestha & Associates' remuneration of ₹25.25 lakh plus taxes for FY 2025-26. The enclosed annual report highlights FY25 revenue of ₹12,207 crore (up 19% year-on-year) and domestic revenue of ₹10,675 crore (up 13%), though adjusted EBITDA declined 25% to ₹3,159 crore with margins contracting 130 basis points to 25.9%, and PAT at ₹2,007 crore (down 3%). The company retained its #1 ranking in prescription share for the 8th consecutive year and maintained an AA+/Stable credit rating from CRISIL and ICRA. Shareholders on the record date of July 31, 2025 are eligible to vote, with remote e-voting open from August 4-6, 2025.
This is a routine AGM notice with standard business items and no material corporate action. The FY25 results reveal a mixed picture: strong topline growth but margin compression and a decline in profitability, which shareholders and prospective investors should monitor going forward.